Domain Thera collaborates with Ono for GPCR-based drug discovery

French drugmaker Domain Therapeutics has signed a collaboration agreement with Japan’s Ono Pharmaceutical (TYO: 4528) focused on discovering small molecules targeting G-Protein Coupled Receptors (GPCRs).

Under the accord, Ono will provide Domain with an upfront payment, pay research funding for the collaborative research programs and success-based milestones on the research and development progress, as well as royalties on sales of the products. Further financial details were not disclosed.

Domain will apply DTect-All, its proprietary GPCR drug discovery platform, and its expertise in GPCR medicinal chemistry and pharmacology to design and optimize small molecules into drug candidates having activity against GPCRs selected by Ono. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical product arising out of the drug discovery collaboration.